Recognizing that the acquisition of rituximab resistance often leads to chemotherapy failure in NHL patients (17), we conducted an investigation into the effects of combining Rituximab with IBTK silencing on cell viability. This evidence concerns the gene IBTK and non-Hodgkin lymphoma.